BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder
Key Highlights
- ➤BullFrog AI (BFRG) achieved milestones in first commercial pharmaceutical project
- ➤Platform identified and prioritized multiple novel MDD therapeutic targets
- ➤Company is applying technology to schizophrenia and bipolar disorder drug targets
Expert Statements
Vin Singh, Founder and Chief Executive Officer of BullFrog AI
“We’ve achieved important milestones and provided essential deliverables in our first commercial project with a global pharmaceutical company, identifying multiple novel and high-quality targets.”
Vin Singh, Founder and Chief Executive Officer of BullFrog AI
“We view this project as crucial commercial scale validation of our technology and believe our successes to date demonstrate the ability of our advanced AI and machine learning technologies to create high value assets.”
GAITHERSBURG, Md., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using its proprietary platform to turn complex biomedical data into actionable insights, announces it has achieved key project milestones under its commercial program with a top 5 global pharmaceutical company. BullFrog AI successfully identified and prioritized novel therapeutic targets for major depressive disorder (“MDD”) by applying its platform to proprietary neuropsychiatric multi-omic data sets.
“We’ve achieved important milestones and provided essential deliverables in our first commercial project with a global pharmaceutical company, identifying multiple novel and high-quality targets,” said BullFrog AI Founder and Chief Executive Officer Vin Singh. “We view this project as crucial commercial scale validation of our technology and believe our successes to date demonstrate the ability of our advanced AI and machine learning technologies to create high value assets.”
Get started
Create a free account to read the full story.